SBIR Phase I: Permanent Attachment of Antimicrobial Peptides to Central Venous Catheters.

SBIR 第一阶段：抗菌肽永久附着于中心静脉导管。

• 批准号: 0712010
• 负责人: Christopher Loose
• 金额: $ 10万
• 依托单位: Semprus Bioscience Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0712010&HistoricalAwards=false
• 关键词: SBIR; Phase; Permanent; Attachment; Antimicrobial

This Small Business Innovation Research phase I research addresses hospital infections which currently afflict 1.7 million patients and kill 99,000 in the US annually, the majority of which are associated with medical devices. Medical devices provide a surface for bacterial growth and, when penetrating the skin, a route for external bacteria to enter the bloodstream. If these infections reach the bloodstream, they lengthen average hospital stays from 5.4 to 20 days and cost up to $50,000 to treat. Existing antimicrobial coatings, which utilize the slow release of metals or other antibiotics, have a limited lifespan and increase concerns of bacterial drug resistance due to the distribution of active agent in the bloodstream. In contrast, SteriCoat is developing a coating in which the antimicrobial agent remains permanently attached to the medical device while providing antimicrobial protection. The broader impact of this development of a highly active, permanent antimicrobial coating, SteriCoat technology will be to help reduce these human and economic costs by preventing infection with fewer side effects and greater efficacy than existing, slow release coatings. The novelty and commercial potential of this technology has been recognized throughout the entrepreneurial community through awards such as first place in both the MIT 100K and the Oxford University business plan competitions. SteriCoat will first produce coated central venous catheters, which have a US market of approximately $350 million, but this highly versatile coating can be applied to devices of any size, shape, or material, leading to a host of follow on products to increase the commercial viability of the product and the impact of the product on the nation's health.

这项小型企业创新研究的第一阶段研究涉及医院感染，目前美国每年有170万患者受到感染，99，000人死亡，其中大部分与医疗设备有关。医疗器械为细菌生长提供了一个表面，并且当穿透皮肤时，为外部细菌进入血液提供了一条途径。如果这些感染到达血液，它们会延长平均住院时间，从5.4天到20天，治疗费用高达50，000美元。现有的抗菌涂层利用金属或其他抗生素的缓慢释放，具有有限的寿命，并且由于活性剂在血液中的分布而增加了细菌耐药性的担忧。相比之下，SteriCoat正在开发一种涂层，其中抗菌剂保持永久附着在医疗器械上，同时提供抗菌保护。 SteriCoat技术是一种高活性、永久性抗菌涂层，其开发的更广泛影响将有助于通过预防感染来降低这些人力和经济成本，与现有的缓释涂层相比，其副作用更少，功效更高。这项技术的新奇和商业潜力在整个创业界得到了认可，获得了麻省理工学院100K和牛津大学商业计划竞赛的第一名等奖项。SteriCoat将首先生产涂层中心静脉导管，其在美国的市场约为3.5亿美元，但这种高度通用的涂层可应用于任何尺寸，形状或材料的设备，从而产生大量后续产品，以提高产品的商业可行性和产品对国家健康的影响。